fluorodeoxyglucose f18 has been researched along with Cystadenocarcinoma, Serous in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Dzul, S; Joiner, M; Miller, SR; Musa, A | 1 |
| Asano, R; Matsuura, T; Miyasaka, N; Otsuka, I; Ouchi, E; Ouchi, T | 1 |
| Chae, SY; Choi, HJ; Kim, HO; Kim, YT; Lee, JJ; Nam, JH; Park, JY; Song, IH; Sung, CO | 1 |
| Dong, A; Wang, Y; Zuo, C | 1 |
| Adachi, K; Arimoto, T; Eguchi, S; Fujii, T; Fujikawa, T; Fujimoto, A; Inoue, T; Kawana, K; Nagamatsu, T; Nakamura, H; Nishida, H; Oda, K; Ogishima, J; Osuga, Y; Sato, M; Taguchi, A; Tomio, K; Wada-Hiraike, O; Yamashita, A; Yoshida, M | 1 |
| Cohn, DE; Farrar, WB; Hall, NC; Martin, EW; Povoski, SP; Seamon, LG | 1 |
| Hong, L; Li, HB; Li, Y; Wang, JL; Wang, Q; Yue, MG | 1 |
| Chung, HH; Chung, JK; Kang, KW; Kang, SB; Kim, JW; Kwon, HW; Park, NH; Song, YS | 1 |
| Berthelsen, AK; Engelholm, SA; Høgdall, C; Høgdall, E; Loft, A; Lundvall, L; Nedergaard, L; Risum, S | 1 |
| Fujibayashi, Y; Kawahara, K; Kotsuji, F; Kurokawa, T; Tsuchida, T; Yonekura, Y; Yoshida, Y | 1 |
| Fujibayashi, Y; Kawahara, K; Kotsuji, F; Kurokawa, T; Okazawa, H; Tsuchida, T; Yonekura, Y; Yoshida, Y | 1 |
| Daraï, E; Dormont, D; Madelenat, P; Zylberberg, B | 1 |
| Katsumata, N; Sawada, M | 1 |
| Jiménez Bonilla, J; Konsvintseva, O; Maldonado Suárez, A; Martín Jorge, R; Moya García, F; Ordovás Oromendía, A; Zomeño Rodríguez, M | 1 |
14 other study(ies) available for fluorodeoxyglucose f18 and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Metastatic spread of serous ovarian carcinoma to the bilateral breasts: a rare presentation.
Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Female; Fluorodeoxyglucose F18; Humans; Ovarian Neoplasms; Tomography, X-Ray Computed | 2022 |
Pretreatment maximum standardized uptake value in 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a prognostic factor for ovarian clear cell carcinoma and low-grade serous carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prognosis; Radiopharmaceuticals; Reference Standards; Reference Values; Retrospective Studies; Survival Rate; Young Adult | 2021 |
The Value of Preoperative Positron Emission Tomography/Computed Tomography in Node-Negative Endometrial Cancer on Magnetic Resonance Imaging.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Preoperative Care; Prognosis; Radiopharmaceuticals; Survival Rate | 2017 |
FDG PET/CT in serous psammocarcinoma of the ovary.
Topics: Adult; Cystadenocarcinoma, Serous; Female; Fluorodeoxyglucose F18; Humans; Multimodal Imaging; Ovarian Neoplasms; Positron-Emission Tomography; Tomography, X-Ray Computed | 2014 |
Low uptake of fluorodeoxyglucose in positron emission tomography/computed tomography in ovarian clear cell carcinoma may reflect glutaminolysis of its cancer stem cell-like properties.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Blotting, Western; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Fluorodeoxyglucose F18; Glutamine; Humans; Middle Aged; Neoplasm Staging; Neoplastic Stem Cells; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Signal Transduction; Tumor Cells, Cultured; Young Adult | 2017 |
Novel perioperative imaging with 18F-FDG PET/CT and intraoperative 18F-FDG detection using a handheld gamma probe in recurrent ovarian cancer.
Topics: Adult; Cystadenocarcinoma, Serous; Female; Fluorodeoxyglucose F18; Humans; Intraoperative Care; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed | 2008 |
[Value of (18)F-FDG imaging and serum tumor markers in the diagnosis of recurrent endometrial carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; CA-125 Antigen; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Endometrial Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Sensitivity and Specificity; Transcription Factors | 2010 |
Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis in patients with epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glycolysis; Humans; Middle Aged; Multimodal Imaging; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2012 |
Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2012 |
Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range.
Topics: CA-125 Antigen; Cystadenocarcinoma, Serous; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed; Whole-Body Counting | 2002 |
Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary.
Topics: Adenocarcinoma, Mucinous; Biomarkers, Tumor; Carcinoma, Endometrioid; Cell Division; Cystadenocarcinoma, Serous; Female; Fluorodeoxyglucose F18; Glucose; Glucose Transporter Type 1; Humans; Ki-67 Antigen; Monosaccharide Transport Proteins; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Radiopharmaceuticals; Tomography, Emission-Computed | 2004 |
Relapse after more than 20 years of follow-up for epithelial ovarian carcinoma.
Topics: Abdominal Pain; Adult; Appendicitis; Axilla; Cystadenocarcinoma, Serous; Diagnostic Imaging; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Radiopharmaceuticals; Time Factors | 2004 |
A case of primary unknown carcinoma with lymphatic spread.
Topics: Cystadenocarcinoma, Serous; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Unknown Primary; Radiography; Radiopharmaceuticals; Tomography, Emission-Computed; Uterine Cervical Neoplasms | 2006 |
[Detection of relapse in ovarian cancer by PET-FDG].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cystadenocarcinoma, Serous; Female; Fluorodeoxyglucose F18; Humans; Ovarian Neoplasms; Ovariectomy; Radionuclide Imaging; Radiopharmaceuticals; Splenic Neoplasms; Tomography, X-Ray Computed | 2001 |